Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CPA1 | P15085 | 7/20 | 0.61 |
| ▸ | CPA3 | P15088 | 3/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.61 |
| ▸ | CPB1 | P15086 | 1/20 | 0.61 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 3/20 | 0.57 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028390 | 0.85 | SLC7A5 (0.53) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL9531957 | 0.85 | CYP1A2 (0.55) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL27377152 | 0.85 | CYP1A2 (0.70) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL2397308 | 0.84 | CYP1A2 (0.48) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL4664822 | 0.83 | CYP1A2 (1.00) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL9007628 | 0.83 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL629350 | 0.83 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL252900 | 0.83 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL27765199 | 0.83 | CYP1A2 (0.68) | CYP1A2CPA1CPA3FOLH1CPB1 | |
| SCHEMBL490150 | 0.82 | CYP1A2 (0.52) | CYP1A2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454502-B2 | Synthesis of deuterated aldehydes | ARIZONA BOARD OF REGENTS ON BEHALF OF ATHE UNIVERSITY OF ARIZONA (US) | 2025-10-28 | — | — | US | disclosed |
| US-20220356139-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-11-10 | — | — | US | disclosed |
| WO-2021045879-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-03-11 | — | — | WO | disclosed |
| US-10259779-B2 | Structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity | WAYNE STATE UNIVERSITY (US) | 2019-04-16 | — | — | US | disclosed |
| US-20180057448-A1 | Structural requirements of histone deacetylase inhibitors: C4-modified saha analogs display dual HDAC6/HDAC8 selectivity | WAYNE STATE UNIVERSITY | 2018-03-01 | — | — | US | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-1343798-A1 | 6-O-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6613747-B2 | Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6472372-B1 | 6-O-Carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002046204-A1 | 6-0-CARBAMOYL KETOLIDE DERIVATIVES OF ERYTHROMYCIN USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10259779-B2 | Structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity | HDAC8, HDAC6, HDAC1 | CYP1A2 2974/4885CPA1 2082/4885CPA3 3165/4885 |
| US-20180057448-A1 | Structural requirements of histone deacetylase inhibitors: C4-modified saha analogs display dual HDAC6/HDAC8 selectivity | HDAC8, HDAC6, HDAC1 | CYP1A2 2974/4885CPA1 2082/4885CPA3 3165/4885 |
| US-12454502-B2 | Synthesis of deuterated aldehydes | ADH1C, ADH1A, CBR1 | CYP1A2 518/4885CPA1 1426/4885CPA3 3679/4885 |
| US-20030013663-A1 | 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS | Q6ZSR9, KDM4E, HK1 | CYP1A2 2899/4885CPA1 2755/4885CPA3 3329/4885 |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | CYP1A2 180/4885CPA1 953/4885CPA3 739/4885 |
| US-20220356139-A1 | SYNTHESIS OF DEUTERATED ALDEHYDES | ADH1C, ADH1A, CBR1 | CYP1A2 518/4885CPA1 1426/4885CPA3 3679/4885 |
| US-20020115620-A1 | 6-0-carbamoyl ketolide antibacterials | Q6ZSR9, HK1, KDM4E | CYP1A2 3028/4885CPA1 2504/4885CPA3 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.